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Abstract 
Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of 
all primary brain tumors.   Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by 
this tumor in its every aspect, including clinical presentation, pathology, genetic signature.  
Current data and treatment strategy in GBM are presented focusing on basic science data and key clinical aspects like surgery, 
including personal experience; adjuvant modalities: radiotherapy, chemotherapy, but also for experimental approaches. Therapeutic 
attitude in recurrent GBM is also widely discussed. 
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Introduction 
Malignant brain tumors are among the cancers with 
the most dismal prognosis and are additionally one of the 
most expensive cancers to treat [1]. The main culprit for 
adult CNS neoplasm is metastasis from other sites 
(especially lung, GI tract, breast cancer). Distinct from 
these, one encounters several types of primary brain 
malignancies, with tumors arising from glial cells (gliomas) 
being the most common. Glioblastoma multiforme (GBM) 
or grade 4 astrocytoma by the classification of World 
Health Organization is the most aggressive and frequent 
of all primary brain tumors [2]; the term “multiforme” 
illustrate the heterogeneity exhibited by this tumor in its 
every aspect, including clinical presentation, pathology, 
genetic signature and response to different therapies [3]. 
Epidemiology 
GBM accounts for 12-15% of all brain tumors and 50-
60% of astrocytomas. The incidence of GBM is less than 
10 to 100,000, but the median survival of a little over 1 
year from diagnosis makes it a considerable public health 
issue [3]. Interestingly, the incidence is fairly constant 
worldwide, leading to the logical inference that 
environmental, geographical and nutritional factors 
probably don’t play a major role in this particular cancer, 
where genetics is more likely to tip the scale of etiology. 
The peak incidence is between 45 and 70 years, with a 
crest to 58 years; only 8.8% of children with central 
nervous system tumors had GBM [4]  and congenital 
cases are extremely rare. A troubling observation, GBM 
incidence is increasing in all age groups, especially in 
adults, which cannot be explained by the aging 
population, better imaging techniques or earlier detection; 
no familial predisposition was found [3]. It is slightly more 
common in men, with a male-to female ratio of 1.5:1 – the 
reasons for this gender distribution are yet unknown [3]. 
Blacks are somewhat protected, as their incidence is 
lower than other ethnic groups like whites, latinos and 
Asians [3]. A study has found GBM patients are generally 
born in winter, particularly in the month of February 
(40%); a perinatal viral origin (infection with an unknown 
oncovirus, integrating in the genome) has subsequently 
been put forward, but no hard evidence has yet been 
found to support it. [3]. The association with an oncogenic 
virus remains controversial; anecdotically, SV40 or 
cytomegalovirus have been involved [3].  Most GBM 
appear to be sporadic, although several genetic disorders 
are associated with increased incidence, including 
tuberous sclerosis, neurofibromatosis type 1 and type 2, 
von Hippel Lindau disease, Turcot and Li-Fraumeni 
syndromes [3]. There is a proven association between 
GBM and exposure to ionizing radiation or polyvinyl 
chloride (a polymer commonly used in construction), but 
no links have been found between GBM and smoking, 
diet, cellular phones or electromagnetic fields [5]. Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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Historical annotations 
1863 – Virchow, cited by [3] was the first one to 
recognize the glial origin of this tumor. 1888 - Bramwell [6] 
is pointing out the surgical dilemma created by the highly 
infiltrative nature of GBM: “the tumor tissue is never 
limited by a capsule and it is impossible to say without 
microscopical examination where the tumor tissue ceases 
and the normal brain tissue begins”. 1914 – Mallory [7] 
coined the term “glioblastoma multiforme”. 1926 - Bailey 
and Cushing definitively changed the name from 
spongioblastoma multiforme to GBM, term also preferred 
by Zulch, Russel and Rubinstein [3]. 1940 - Scherer and 
Kernohan recognized GBM sometimes develops by 
progression from a lower grade lesion; the idea was later 
on sustained by molecular studies showing a 
characteristic sequential accumulation of genetic 
alterations from diffuse astrocytoma (WHO grade II) to 
anaplastic (grade III) and to GBM. Most cases, however, 
are thought to arise de novo. Scherer [8] has also paid 
due attention to the migration of tumor cells away from the 
main tumor mass through the brain parenchyma, 
describing the “secondary structures of Scherer”. 
Clinical considerations 
Occasionally,  GBM  is asymptomatic until  it  reaches 
an enormous size. History is generally short, less than a 
few months and not uncommonly symptoms begin 
abruptly; in more than 50% of cases, this is explained by 
the rapid development of increased intracranial pressure, 
with compression and infiltration of the surrounding brain 
[3]. Physical findings depend on the location, size and 
rate of growth of the tumor, as with any other CNS tumor: 
headache, partial or generalized seizures in 30-60% of 
patients,  contralateral slowly progressive hemiparesis, 
sudden onset of hemiplegia with depressed level of 
consciousness – as a stroke in evolution [9], generated by 
intratumoral bleeding, directly correlated with the level of 
expression of vascular endothelial growth factor (VEGF) 
[10];  sensory disturbances,  subtle personality changes, 
visual field defects. As survival gets longer, an increasing 
number of patients experience: cognitive problems, 
neurologic deficits resulting from radiation necrosis, 
communicating hydrocephalus, occasionally cranial 
neuropathies, polyradiculopathies from leptomeningeal 
spread. 
Genetics 
Overexpression of several oncogenes and mutations 
leading to loss of function of key tumor suppressor genes 
concur to create one of the most aggressive cancers. 
Amplification of oncogenes such as the epidermal growth 
factor receptor (EGFR), as well as loss of tumor 
suppressors like PTEN on chromosome 10, p53 on 
chromosome 17, or p16/INK4A are some of the most 
common genetic alterations in GBM [11, 12].  Adult 
malignant astrocytoma was one of the first cancers shown 
to have frequent TP53 mutations [13, 14]. The p53 
disfunction disrupts the downstream p14ARF pathway, 
impedes the process of apoptosis and fosters further 
genomic instability. Most commonly, the mutations occur 
with loss of the remaining wild-type allele, such that the 
tumor cells express only aberrant p53 [14]. This 
distribution of mutations is highly similar to those indicated 
in other human cancers and in which codons 175, 248, 
273 are revealed as the most common targets of 
alteration, contributing substantially to the overall high 
incidence of alterations in p53’s DNA binding domain. 
GBMs are often classified with respect to their clinical 
history: either as primary GBM, without indication of 
association with a lower malignancy precursor or as 
secondary GBM, having evolved from a lower grade 
astrocytoma. For the latter, which constitute <10% of all 
GBM, TP53 mutations are frequent and occur in nearly 
two-thirds of the cases [14]. For the more common 
primary GBM, only 25-30% of the cases have p53 
mutations. In total and without subclassification, 
approximately two thirds of all GBM have wild-type p53 
status. The clinical division in primary and secondary 
GBM is also relevant from a basic science point of view, 
as different genetic events are incriminated in their 
development [3]. For primary GBM, the main factors are 
considered to be EGFR amplification, loss of PTEN and 
INK4A [16]; all occurring almost simultaneously or in a 
brief period of genomic instability, correlating with a rapid 
clinical history, often shorter than 3 months. For 
secondary GBM, there is a distinct succession of genetic 
events and the course is longer: initially, activation of 
signal transduction pathways, usually through 
overexpression of PDGF, PDGFR, FGF2 (instead of 
EGFR); p53 mutation, CDK4 amplification, Rb 
(retinoblastoma gene) loss and eventually, loss of PTEN 
unleashes the Akt pathway, leading to downstream 
activation of mTOR (mammalian target of rapamycin) and 
other genes (NF-kB, an important transcription factor 
promoting proliferation; GSK3; anti-apoptotic genes such 
as BAD etc.) with devastating consequences [16].  The 
main way of activating Ras in GBM is through EGFR 
(either overexpressed and stimulated by exogenous 
growth factors, or constitutively active [17] as is the case 
for certain mutant variants, like the truncated EGFRvIII) 
but binding of different growth factors to other tyrosine 
kinase receptors is another important upstream event. For 
the rare pediatric GBM, it is believed that EGFR signaling 
is revived up by overexpression of YB-1 (Y-Box binding 
protein 1). Things, unfortunately, are incredibly more 
complex than the deregulation of a few signaling 
pathways. For instance, differential recruitment of mRNAs 
to polysomes (thus optimizing protein synthesis) 
contributes to glioma formation, being an important player 
in the oncogenic Ras and Akt signaling [18]. Such Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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observations lead to cell-existential questions like [3]: 
transcriptional control versus translational control, which 
is more essential to cell transformation? Does aberrant 
regulation of translation lead to cancer? Would it be a 
cause or consequence of cancer progression? 
Pathology 
GBM is preferentially located supratentorially - fewer 
than 50 cerebellar cases have been described in literature 
[3], in the cerebral hemispheres, more often in the frontal 
lobes than the temporal lobes or basal ganglia (although a 
combined fronto-temporal mass is particularly typical of 
GBM). GBM of the brainstem (malignant brain stem 
glioma) are quite infrequent and often affect children [19], 
while spinal cord is a rare site for this neoplasm - if it 
occurs, the cervical and thoracic segments are most likely 
to be affected; when concomitant with a brain mass, some 
possibly develop as a “drop pseudo-metastasis” from 
tumor cells that invaded the ventricular system. It usually 
presents as an irregular mass in the white matter, 
infiltrating the surrounding parenchyma by coursing along 
white matter tracts. Although tumor cells are considered 
to be already disseminated at time of diagnosis far in the 
surrounding parenchyma, it is generally a single mass, 
while true multifocal glioblastoma  usually have distinct 
histological appearance and are most likely policlonal, 
usually presenting as simultaneous infra and 
supratentorial masses - incidence of 2,5% [20, 21]. Most 
GBMs are intraparenchymal with an epicenter in the white 
matter, some are largely superficial, in contact with the 
leptomeninges and dura, but without invading the 
subarachnoid space. Tipically unilateral, involving much of 
an entire lobe, not uncommonly it involves the corpus 
callosum and crosses the midline to produce the 
characteristic "butterfly" appearance of bilateral invasion. 
Grossly, it appears topographically diffuse, a poorly 
delineated mass with no capsula, with prominent areas of 
old and recent hemorrhage (extensive areas of yellowish-
brown to red discoloration) and necrosis (as much as 80% 
of the total tumor mass), cystic areas sometimes 
alternating with firm tissue. Microscopically, characteristic 
histopathological features include: cellular and nuclear 
polymorphism, nuclear atypia, high mitotic activity, 
vascular trombosis, microvascular proliferation and 
necrosis, with regions of pseudopalisading (created by 
viable tumor cells bordering areas of necrosis). Among 
the above, the presence of necrosis within the tumor is 
considered crucial, showing the aggressiveness of the 
cells (they outgrow the blood supply, regardless of their 
angiogenic potential) and it is a sine-qua-non diagnostic 
criterion to histopathologically “upgrade” an anaplastic 
astrocytoma to GBM. Another important diagnostic clue is 
the presence of secondary structures such as 
perineuronal and perivascular “satellitosis” – a result from 
the interaction of glioma cells with host brain structures, 
especially in certain regions, like the subpial zone of the 
cortex, in the subependymal region, and through the white 
matter tracts (intrafascicular spread, considered a 
“favorite” route of migration and invasion for the tumor 
cells). The cell composition is heterogenous (again – 
“multiforme”), especially for GBM resulting from 
progression of diffuse astrocytomas (grade II): fusiform, 
round, pleomorphic (small, undiferentiated, lipidized, 
granular, giant) astrocytes – may reflect the emergence of 
a new tumor phenotype through stepwise acquisition of 
genetic alterations. Histologic tumor variants which do not 
alter the prognosis of the tumor (with the exception of 
gliomatosis who has no surgical management and a more 
accelerated course), include: giant cell glioblastoma, 
gliosarcoma and gliomatosis cerebri. Extension within and 
along perivascular spaces are common, but invasion of 
the vessel lumen seems to occur infrequently, correlating 
with a very low incidence of haematogenous spread to 
extraneural tissues. Metastatic spread of GBM occurs in 
less than 5% of cases, late in the illness course and it was 
almost unheard of before the adjuvant therapy. 
Dissemination within the CSF pathways is so rare that it 
does not seem to justify the use of prophylactic irradiation 
of the spinal cord [3]. In practice, GBM metastasis is 
considered an exceptional event. Local dissemination into 
subcutaneous tissues of the scalp, face and neck can 
occur if dura is not closed at the time of surgery. 
Penetration of dura is possible, although not frequent, 
while invasion of venous sinuses and bone is exceptional; 
peritoneal metastasis via ventriculoperitoneal shunt is 
also a possibility [3]. 
Imaging 
MRI with and without contrast is the most sensitive 
and specific study, particularly useful in evaluating tumor 
extension and subacute and chronic hemorrhage 
collections [3]. On T1-weighted images, the mass has low-
signal intensity, presenting as a central hypodensity 
surrounded by a thick enhancing rim of tumor with thick, 
irregular walls, corresponding to the cellular and highly 
vascularized peripheral area of the neoplasm. Marked 
gadolinium enhancement indicates angiogenesis and 
vascular permeability. The tendency to infiltrate along the 
white matter tracts and involvement or crossing of the 
corpus callosum can also be observed. On T2-weighted 
images, it appears as a high-signal intensity mass, 
however the area is broader, less well defined and 
overlaps with the surrounding vasogenic edema; this 
imaging modality is best at revealing the perilesional 
edema.  The CT scan appearance is variable and less 
informative and cannot replace the MRI as study of choice 
despite advantages of cost and time [3]. It typically shows 
irregularly shaped lesions with peripheral ring-like zone of 
contrast enhancement around a dark, central area of 
necrosis, usually inhomogeneous. Surrounding edema 
has a hypodense or isodense appearance.  Functional 
imaging, such as positron-emission tomography (PET Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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scan), single-photon emission computed tomography or 
MR spectroscopy, although cost-prohibitive for routine 
clinical practice, may provide useful information. The level 
of regional consumption of radioactively labeled glucose 
(used in PET scanning) correlates with cellular 
metabolism and reduced survival. These techniques may 
help differentiate the tumor from other benign mass 
lesions, brain abscess, toxoplasmosis and help refine the 
differential diagnosis between treatment-related radiation 
necrosis versus tumor recurrence, so difficult to 
distinguish in MRI or otherwise (e.g. levels of choline and 
lipids are different on MR spectroscopy). They may also 
be helpful to define the margins of the tumor for surgical 
resection, planning for the radiation fields and to improve 
the diagnostic accuracy in case a small biopsy sample is 
taken [3]. 
Differential diagnosis 
Other primary brain tumors (meningioma, metastasis, 
astrocytoma, oligodendroglioma); features making GBM a 
more likely diagnosis include the irregular shape of the 
mass, the central necrosis, the extensive surrounding 
edema and mass effect. Metastasis should always be 
considered; it is less likely when the patient is realtively 
young and has no history of a primary tumor.  Brain 
abscess should also be mentioned but it is typically 
identifiable as a thin, regular rim of enhancement around 
a central cavity. Other infections (toxoplasmosis, 
cysticercosis) may also have a close radiologic 
appearance.  Primary CNS lymphoma may be, 
occasionally, "butterfly-shaped" involving the corpus 
callosum. Multiple sclerosis lesions - “concentric sclerosis 
of Balo”, a borderline rare form of multiple sclerosis [22] 
may be difficult to separate from GBM by clinical 
presentation and radiologic appearance. 
Treatment 
Several factors concur to make GBM treatment 
notoriously difficult. First, the tumor cells themselves, 
despite their relatively rapid cycle, are quite resistant to 
conventional therapies. In addition, brain has a limited 
capacity to repair itself, any damage may be definitive and 
consequential. Last but not least, before the advent of 
temozolomide (TMZ), adequate penetration of the blood-
brain barrier (BBB) by chemotherapeutics could not be 
achieved without dose-limiting systemic side effects [3]. 
The mainstay of therapy consists of surgery, radiation and 
chemotherapy. Objectives of surgery range from merely 
confirming the diagnosis (biopsy), to alleviating symptoms 
of mass effect and ICP (debulking or cytoreductive 
surgery, resecting as much as it is safe without worsening 
patient’s neurologic deficits), to aggressive attempts to 
improve not only the quality of life, but also influence 
survival significantly. In addition to tumor-targeted 
therapy, one has to treat several associated phenomena 
[3]. 
Peritumoral edema may respond to a potent 
corticosteroid (Dexamethasone) given 4 to 10 mg every 4 
to 6 h, diminishing mass effect and lowering intracranial 
pressure, with a decrease in headache and drowsiness. 
Seizures treatment is required to only 40% of 
patients. An appropriate anticonvulsant, with minimal side 
effects and cytochrome P450 interference (enzyme 
inducers can increase the metabolism and clearance of 
some chemotherapeutic agents), should first be tried as 
monotherapy. 
Prevention of thromboembolic disease is a major 
concern for patients with GBM, as the incidence has been 
reported to be as high as 35-40%. Prophylactic use of 
anticoagulation has not been recommended because of 
increased risk of intracranial hemorrhage; alternatives 
include appropriate mobilization and physical therapy, calf 
protection such as SCDs (sequential compressive 
devices) and radio-interventional placement of an inferior 
vena cava filter (Greenfield® filters). 
Occupational, speech therapy, emotional and 
psychological support are also important, especially as 
the emphasis shifts to palliative and supportive care (a 
point reached, unfortunately, in the evolution of a majority 
of GBM patients). 
Surgery 
Bennett and Godlee are credited with the first 
successful removal of a glial tumor (1884), cited by Iacob 
[3]. The extent of surgical resection depends on location 
and eloquence of the brain areas involved, but surgery is 
always an incomplete debulking, since GBM is a highly 
infiltrating tumor and cannot be resected completely. In a 
seminal study by Wilson [23], the percentage of tumor 
cells in the entire cell population was quantified as a 
function of distance from the „visible” tumor edge and the 
averages were found to be 6% at 0-2 cm away (hence, 
the margin considered for „radical” resection should not 
be less than 2 cm) and more troubling, 1.8% for 2-4 cm 
and 0.2% at more than 4 cm away (e.g., in the 
contralateral hemisphere). Whether aggressive, “radical” 
surgery prolongs survival is still debatable, but several 
studies suggest a close inverse correlation between 
survival and the amount of residual tumor observed on 
postoperative MRI scans [24]. Partisans of radical 
resection maintain several advantages, such as: good 
relief of ICP, reversal of some neurologic deficits, lowering 
seizure incidence or even abolishing them, a definitive 
pathology diagnosis by reducing sampling error and the 
assumption that a “more cytoreductive” surgery may 
facilitate adjuvant treatment modalities and ultimately 
improve survival. Arguments against radical resection 
stem from the inherent invasiveness of GBM, which 
cannot be totally resected anyway; in addition, there might 
be a potential for facilitating tumor cells migration by the Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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act of surgery and the possibility of surgical complications, 
new neurological deficits (thinking to “primum non 
nocere”, “first, do no harm”). If pursued, radical resection 
may be improved by careful pre-operative planning, use 
of intraoperative MRI or at least 3D - image guidance for 
tumor delineation and electrophysiological mapping to 
help preserve eloquent areas; also, use of 5-
aminolevulinic acid (ALA) for influencing fluoresceine-
guided resections has recently been reported to increase 
survival (median of 17.7  months vs. 12.9 months) [25]. 
The routine use of robot arms has not yet been proven to 
influence survival [3]. 
Radiation therapy 
Early clinical trials revealed a modest, yet undeniable 
efficacy of external beam radiotherapy (RT) in treating 
GBM, based on the damage of ionizing radiation in the 
DNA helix by electrons and free radicals. RT is usually 
started within 4 to 6 weeks after surgery [26] and 
administered in a standard fractionated regimen over 6 to 
7 weeks [27, 28].  The standard dose of external beam 
RT is 60 Gy in single daily fractions of 1.7-2 Gy, 5 times a 
week, applied to a limited field that includes the 
enhancing volume on CT scans with a 2-3 cm margin or 2 
cm margin beyond Flair T2-weighted MR images. Whole 
brain RT does not improve survival when compared to the 
more precise and targeted three-dimensional conformal 
RT. Targeted variants of RT have been developed that 
are so focused, that they are closer to surgery – hence 
their generic name, radiosurgery. The Gamma knife has 
been introduced half a century ago by Lars Leksell and is 
now at its 4th generation, the Leksell Perfexion (introduced 
in clinical practice in 2007), boasting 201 sources of 60Co. 
These devices triangulate hundreds of gamma rays (of 
low individual energy) in a single spot, so “ground zero” 
receives a very high dose of radiation, with a sharp 
decline in exposure for the surrounding tissue. The 
Cyberknife and LINAC are other highly focused 
radiosurgery systems. This technique is generally used to 
treat small (<3 cm), radiographically well-defined lesions 
in surgically inaccessible or eloquent areas of the brain or 
in patients with serious coexisting medical illnesses, 
unsuitable for open resection. Growth of the tumor during 
the course of radiation is an extremely poor prognostic 
sign. A major reason for radioresistance is the 
significantly lower oxygenation of tumors compared to 
surrounding cortex [29]. This may be quantified by 
measuring the level of a transcription factor, hypoxia-
inducible factor-1 alpha (HIF-1a), a hypoxic sensor that is 
also an ominous indicator of tumor radioresistance. 
Stereotactic brachytherapy involves using stereotactic 
techniques to accurately place radioactive isotopes: 125I, 
252Californium within the tumor. Typically, brachytherapy 
delivers an additional 50-60 Gy of radiation, bringing the 
total dose of radiation up to 110-120 Gy. This is indicated 
in patients with unifocal, well-defined, supratentorial 
tumors less than 5 cm in diameter that do not involve the 
corpus callosum, brain stem or ependymal surfaces; 
currently as a salvage modality, in recurrent GBM after 
repeat resection of the tumor. Recently, instead of solid 
seeds, a variant has been developed where a temporary 
balloon catheter filled with liquid radiation is implanted - 
the GliaSite RTS (radiotherapy system). The device is an 
inflatable, silicone, balloon catheter that is inserted in the 
resection cavity and filled with an aqueous solution of 
organically-bound 125I (Iotrex), which delivers 40-60 Gy at 
0.5-1 cm from the balloon surface over a course of 3-7 
days. Another adjuvant modality, thermotherapy, involves 
microwave antennas operating at 2450 or 915 MHz to 
deliver heat for one hour at 450C before and after 3-5 
days of interstitial brachytherapy. Boron neutron capture 
therapy (BNCT) is an experimental form of RT where the 
damage occurs through the interaction between a beam 
of thermally slowed neutrons (created in a mini-nuclear 
reactor) with boron -10, which is injected to a patient and 
preferentially binds to tumor cells. Still investigational and 
costly, this is a treatment modality with great promise: 
Hatanaka [30] reported a 5-year survival rate of 50% with 
few complications, after combining intra-arterial 
polyhedral boron anion with focused thermal neutron 
radiation.  The mean survival after optimal surgery and 
adjuvant RT (60 Gy) is about a year: 12.1 months in one 
of the latest studies [27]. There are several limitations to 
RT that make adjuvant chemotherapy a must: the 
infiltrative nature of GBM, the risk of radiation necrosis 
and radiation-induced permanent neuronal damage (e.g. 
radiation encephalopathy), as well as the radio-resistance 
of some tumors, intrinsic or acquired. 
Chemotherapy 
In attempts to further improve survival beyond that 
offered by RT, many chemotherapeutics have been tested 
for effectiveness in the treatment of GBM. Among these, 
alkylating agents have demonstrated some benefit; either 
chloroethylating drugs like carmustine (BCNU), lomustine 
(CCNU) or methylating agents like temozolomide (TMZ), 
are used in the majority of GBM clinical protocols [31]. 
The chloroethylating agents readily penetrate the blood-
brain barrier due to high hydrophobicity and they can also 
be administered orally [32]. They act by forming O6-
chloroethylguanine lesions, which lead to G-C interstrand 
crosslinks [33], after a mean time of only 10 hours (8-12h) 
[34]. It is thought that as few as 2 to 5 such lesions 
(interstrand crosslinks) can trigger apoptosis in a tumor, 
as well as a normal, cell [35, 36]. However, an aggressive 
regimen with these agents causes considerable side 
effects [37], leading to dose reductions and corresponding 
decreases in therapeutic efficacy.  Methylating agents 
such as TMZ show reduced toxicity toward normal cells 
and are much better tolerated. Oral administration of 
TMZ, either concomitant with radiotherapy, followed by 
adjuvant TMZ or as adjuvant TMZ alone after completion Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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of radiation, is increasingly becoming standard of care for 
GBM patients, at least in those countries that can afford 
the high cost of TMZ therapy [37, 38]. The use of TMZ 
has been significantly increased as a result of a phase III 
trial that showed survival advantage to newly diagnosed 
GBM patients receiving TMZ with standard radiotherapy 
[27]. Regarding its mechanism of action, O6-
methylguanine (O6-mG) is perhaps the most biologically 
relevant lesion generated by TMZ; consequently, TMZ 
therapy has little effect in tumors where the added methyl 
group is removed due to the intact enzymatic activity of 
O6-methylguanine-DNA-methyltransferase (MGMT) [31, 
39-41]. The importance of MGMT epigenetic silencing 
through promoter methylation was shown as a favorable 
prognostic factor for improved response to TMZ in a multi-
institutional study of GBM patients [28]. However, 
additional analysis of the results of this study [28] showed 
that 10% of the patients having tumors with non-
methylated MGMT survived more than 2 years, which is 
considered long-term survival for GBM patients. This 
observation indicates that MGMT methylation status is not 
the sole predictor of GBM response to TMZ and this drug 
of choice should not be withheld from any GBM patient, 
unless enrolled in investigational trials.  Second-line 
cytotoxic agents, for patients who do not respond to the 
first-line drugs discussed above, include carboplatin, 
etoposide, oxaliplatin, and irinotecan. Sometimes, 
procarbazine and vincristine may be added to CCNU 
(lomustine) as the PCV regimen, which used to be a first 
line approach before the supremacy of TMZ. A few other 
chemotherapy approaches warrant a brief mention. 
Gliadel  is a small wafer that contains the 
chemotherapeutic drug carmustine (BCNU) and a 
biodegradable polyanhydride copolymer. Up to 8 Gliadel 
wafers are implanted in the resection cavity, designed to 
release BCNU slowly over a period of 2-3 weeks. Clinical 
trials results have shown that Gliadel prolonged survival in 
a statistically significant (albeit modest) manner in both 
newly diagnosed patients and patients with recurrent 
glioblastoma multiforme when used as adjunctive therapy 
to surgery and/or radiation therapy - 13,9 months 
compared to placebo implants - 11,6 months [42]. Nota 
bene, Gliadel wafers may have terrible side-effects: 
seizures, brain edema, wound healing problems, 
intracranial infections, delay in the administration of other 
drugs. Chronic administration of chloroquine – 150-300 
mg dose of chloroquine daily starting 1 day after surgery - 
greatly enhanced the response of GBM to antineoplastic 
treatment. Because the cytotoxicity of chloroquine on 
malignant cells is negligible, these favorable results 
appear mediated by its strong antimutagenic effect that 
precludes the appearance of resistant clones during 
radiotherapy and chemotherapy [43]. Other experimental 
approaches to the chemotherapy of GBM include: anti-
angiogenic agents like anti-VEGF monoclonal antibodies, 
e.g. Bevacizumab (Avastin), anti-FGF antibodies, 
monoclonal antibodies targeting EGFR like Erlotinib and 
Gefitinib; inhibitors of other tyrosine kinase receptors (e.g. 
PDGFR); inhibitors of kinesin Eg5; mTOR inhibitors like: 
Everolimus, Sirolimus, Temsirolimus; farnesyl-transferase 
inhibitors like: Tipifarnib, Lonafarnib. A promising avenue 
of individualized research is an antitumoral vaccine made 
from specific proteins isolated from glioblastoma cells 
following resection, in order to generate a specific 
immune response to that particular tumor [44]. 
Authors’ experience 
We analyzed data from 118 patients with a final 
histopathological diagnosis of GBM, treated in the 
Neurosurgery Clinic of the University Hospital, Bucharest, 
in the last 6 years (2003-2008). Patients received either 
surgery or biopsy and adjuvant therapy in the form of 
radiotherapy, chemotherapy, following standard protocols. 
Overall, the median survival was 49 weeks. There was a 
significant difference in survival between the 73 patients 
who have undergone resection (57 weeks) and the 45 
patients who were only biopsied (38 weeks) (p<0.01). 
Obviously, this difference is at least partly due to selection 
bias, as patients with multifocal and large bilateral tumors 
(“butterfly GBM”) who presented in an advanced 
consumptive state (poor Karnofsky scores) or who were 
not good candidates for extensive open surgery due to 
advanced age and comorbid disorders, were more often 
offered biopsy. Table 1 presents prognostic factors and 
survival in our cohort as a function of age, confirming that, 
contrary to many other malignancies, younger is better for 
GBM patients. 
Management of recurrent GBM 
Semantically [3], there are two distinct clinical 
entities: 
1)  Tumor  recurrence: after complete surgical 
removal of the visible mass, documented radiologically 
(MRI), the tumor re-appears after a variable free interval, 
usually within 2 cm of the original site (correlate with [23]), 
although 10% of patients may develop new lesions at 
distant sites. 
2)   Tumor progression: after a subtotal excision, 
the mass never disappears completely from imaging 
studies and after a while there is radiological 
documentation of an increase in tumor size. 
There are many factors favoring recurrence: subtotal 
excision (either erroneously or intentional, in order to 
protect eloquent areas); tumor multicentricity; 
histopathological features of aggressiveness (extensive 
angiogenesis, high mitotic index etc.), genetic features 
(deregulated genome with many mutations accumulated); 
clinical factors (e.g. Karnofsky score, age, comorbidities, 
other factors that may influence administration of adjuvant 
therapy) and perhaps most important, the inherent 
infiltrative nature of GBM – at the time of diagnosis, there Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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are already malignant cells disseminated at a distance 
from the bulk of the tumor, mocking the scalpel. 
Recurrence usually means the tumor is becoming more 
aggressive, genetically and clinically and it has acquired 
resistance to the adjuvant therapy. For the patients and 
their families, it is important to do something to offer a 
longer life expectancy, maintaining at the same time a 
good quality of life for a reasonable period, without 
supplementary neurological deficits. For the society, the 
most embarrassing problem is the costs of different 
procedures: surgery, chemotherapy, radiotherapy. For the 
neurosurgical community, reoperation for recurrent 
malignant gliomas is still a difficult dilemma. So what is to 
be done for these patients? Unfortunately,  additional 
radiation has limited control on further tumor growth and 
would potentiate neurologic toxicity. It has been shown 
that prior chemotherapy had significant correlations with 
time to tumor progression and survival, but further cycles 
of chemotherapy are problematic in these patients, due to 
their biological status and the heightened risk of 
cumulative myelotoxicity (as the recurrence is usually fast, 
contrary to some other cancers). Radiosurgery may be an 
option, for tumors of appropriate size, pattern and 
location. Open surgery is also to be considered, it could 
be life saving to patients with lesions that produce 
increased intracranial pressure and mass effect. From a 
life quality standpoint, to selected patients with recurrent 
GBM, repeat surgery could be beneficial and a 
reasonable therapeutic alternative. If the tumor is better 
circumscribed on recurrence, extensive removal is 
indicated, as radical as first-time surgery. On the contrary, 
patients over 60 years old, with bad preoperative function, 
low performance status and a short symptom free period 
after the first surgery, have a bad prognosis. Significant 
peritumoral edema, symptomatic mass effect, location 
near eloquent areas are other negative prognostic factors 
for surgery. Timing is also important. If tumor recurrence 
occurred within 6 months after a radical resection and  
radiotherapy, progression or recurrence after second 
surgery are much quicker; in case a year or more has 
passed after the initial presentation, it would be 
worthwhile to excise the recurrent tumor. 
Conclusions 
The prognosis of GBM is still dismal. Without 
treatment, the median survival from the diagnosis is 3 
months (death is usually due to cerebral edema and 
increased intracranial pressure). With maximal treatment, 
median survival is only 14 months, despite major 
improvements in neuroimaging, neurosurgery, radiation 
treatment techniques and the advent of temozolomide - 
“bullets but no magic”- [45]. The survival at 2 years is 16% 
and at 3-years is 5%. Only approximately one in 5000 
GBM patients survives for decades. That being said, 
patients with GBM are not universally incurable, with an 
ever increasing albeit small fraction of patients who fight 
and survive the disease. Progress in improved outcomes 
for GBM patients will require the identification and 
development of therapeutics with high specificity for brain 
tumor cells and that have the ability to access the entire 
intracranial compartment. 
 
 
 
Age group  Median survival 
(number of patients) 
20-40  68 weeks (19) 
40-60  57 weeks (35) 
> 60  40 weeks (68) 
Favorable prognostic 
factors 
Unfavorable 
prognostic factors 
Age 20-40  Age > 60 
Karnofsky score > 70  Karnofsky score < 70 
Resection  Biopsy Only 
Single mass  Multifocal tumor 
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